Psychiatry

Back to articles

FDA approves 3-month paliperidone injection

KEY POINT

A 3-month formulation of paliperidone (Invega Trinza—Janssen) was recently approved by FDA, with data showing that this agent significantly delayed the time to relapse of symptoms in patients with schizophrenia and was generally well tolerated.